Jason S Williams, Adam T Higgins, Katie J Stott, Carly Thomas, Lydia Farrell, Cleo S Bonnet, Severina Peneva, Anna V Derrick, Trevor Hay, Tianqi Wang, Claire Morgan, Sarah Dwyer, Joshua D'Ambrogio, Catherine Hogan, Matthew J Smalley, Lee Parry, Paul Dyson
BACKGROUND: Bacterial cancer therapy was first trialled in patients at the end of the nineteenth century. More recently, tumour-targeting bacteria have been harnessed to deliver plasmid-expressed therapeutic interfering RNA to a range of solid tumours. A major limitation to clinical translation of this is the short-term nature of RNA interference in vivo due to plasmid instability. To overcome this, we sought to develop tumour-targeting attenuated bacteria that stably express shRNA by virtue of integration of an expression cassette within the bacterial chromosome and demonstrate therapeutic efficacy in vitro and in vivo...
March 23, 2024: Cell & Bioscience